| Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe S Flaxman, S Mishra, A Gandy, HJT Unwin, TA Mellan, H Coupland, ... Nature 584 (7820), 257-261, 2020 | 4255* | 2020 |
| Future challenges for clinical care of an ageing population infected with HIV: a modelling study M Smit, K Brinkman, S Geerlings, C Smit, K Thyagarajan, A van Sighem, ... The Lancet infectious diseases 15 (7), 810-818, 2015 | 898 | 2015 |
| Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study AB Hogan, BL Jewell, E Sherrard-Smith, JF Vesga, OJ Watson, ... The Lancet global health 8 (9), e1132-e1141, 2020 | 892 | 2020 |
| HIV and risk environment for injecting drug users: the past, present, and future SA Strathdee, TB Hallett, N Bobrova, T Rhodes, R Booth, R Abdool, ... The Lancet 376 (9737), 268-284, 2010 | 667 | 2010 |
| Towards an improved investment approach for an effective response to HIV/AIDS B Schwartländer, J Stover, T Hallett, R Atun, C Avila, E Gouws, M Bartos, ... The Lancet 377 (9782), 2031-2041, 2011 | 642 | 2011 |
| Why large-scale climate indices seem to predict ecological processes better than local weather TB Hallett, T Coulson, JG Pilkington, TH Clutton-Brock, JM Pemberton, ... Nature 430 (6995), 71-75, 2004 | 604 | 2004 |
| HIV decline associated with behavior change in eastern Zimbabwe S Gregson, GP Garnett, CA Nyamukapa, TB Hallett, JJC Lewis, PR Mason, ... Science 311 (5761), 664-666, 2006 | 459 | 2006 |
| HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa JW Eaton, LF Johnson, JA Salomon, T Bärnighausen, E Bendavid, ... PLoS medicine 9 (7), e1001245, 2012 | 458 | 2012 |
| Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models BL Jewell, E Mudimu, J Stover, D Ten Brink, AN Phillips, JA Smith, ... The lancet HIV 7 (9), e629-e640, 2020 | 446 | 2020 |
| Requirements for global elimination of hepatitis B: a modelling study S Nayagam, M Thursz, E Sicuri, L Conteh, S Wiktor, D Low-Beer, ... The Lancet Infectious Diseases 16 (12), 1399-1408, 2016 | 419 | 2016 |
| Building a tuberculosis-free world: The Lancet Commission on tuberculosis MJA Reid, N Arinaminpathy, A Bloom, BR Bloom, C Boehme, R Chaisson, ... The Lancet 393 (10178), 1331-1384, 2019 | 394 | 2019 |
| Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? MS Cohen, MK Smith, KE Muessig, TB Hallett, KA Powers, AD Kashuba The Lancet 382 (9903), 1515-1524, 2013 | 317 | 2013 |
| Examining the promise of HIV elimination by ‘test and treat’in hyperendemic settings PJ Dodd, GP Garnett, TB Hallett Aids 24 (5), 729-735, 2010 | 311 | 2010 |
| Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model A Heffernan, GS Cooke, S Nayagam, M Thursz, TB Hallett The Lancet 393 (10178), 1319-1329, 2019 | 303 | 2019 |
| Mathematical models in the evaluation of health programmes GP Garnett, S Cousens, TB Hallett, R Steketee, N Walker The Lancet 378 (9790), 515-525, 2011 | 289 | 2011 |
| Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study SJ Anderson, P Cherutich, N Kilonzo, I Cremin, D Fecht, D Kimanga, ... The Lancet 384 (9939), 249-256, 2014 | 281 | 2014 |
| Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti TB Hallett, J Aberle-Grasse, G Bello, LM Boulos, MPA Cayemittes, ... Sexually transmitted infections 82 (suppl 1), i1-i8, 2006 | 266 | 2006 |
| A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? DT Halperin, O Mugurungi, TB Hallett, B Muchini, B Campbell, T Magure, ... PLoS medicine 8 (2), e1000414, 2011 | 261 | 2011 |
| Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study X Li, C Mukandavire, ZM Cucunubá, SE Londono, K Abbas, HE Clapham, ... The Lancet 397 (10272), 398-408, 2021 | 253 | 2021 |
| Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical … JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ... The Lancet Global Health 2 (1), e23-e34, 2014 | 238 | 2014 |
John StoverAvenir Healthavenirhealth.org üzerinde doğrulanmış e-posta adresine sahip